1. Home
  2. CHSCN vs HUMAW Comparison

CHSCN vs HUMAW Comparison

Compare CHSCN & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHSCN
  • HUMAW
  • Stock Information
  • Founded
  • CHSCN N/A
  • HUMAW 2004
  • Country
  • CHSCN United States
  • HUMAW United States
  • Employees
  • CHSCN N/A
  • HUMAW 220
  • Industry
  • CHSCN Farming/Seeds/Milling
  • HUMAW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHSCN Industrials
  • HUMAW Health Care
  • Exchange
  • CHSCN Nasdaq
  • HUMAW Nasdaq
  • Market Cap
  • CHSCN N/A
  • HUMAW N/A
  • IPO Year
  • CHSCN N/A
  • HUMAW N/A
  • Fundamental
  • Price
  • CHSCN $25.19
  • HUMAW $0.60
  • Analyst Decision
  • CHSCN
  • HUMAW
  • Analyst Count
  • CHSCN 0
  • HUMAW 0
  • Target Price
  • CHSCN N/A
  • HUMAW N/A
  • AVG Volume (30 Days)
  • CHSCN N/A
  • HUMAW 14.2K
  • Earning Date
  • CHSCN N/A
  • HUMAW 03-21-2025
  • Dividend Yield
  • CHSCN N/A
  • HUMAW N/A
  • EPS Growth
  • CHSCN N/A
  • HUMAW N/A
  • EPS
  • CHSCN N/A
  • HUMAW N/A
  • Revenue
  • CHSCN N/A
  • HUMAW N/A
  • Revenue This Year
  • CHSCN N/A
  • HUMAW N/A
  • Revenue Next Year
  • CHSCN N/A
  • HUMAW N/A
  • P/E Ratio
  • CHSCN N/A
  • HUMAW N/A
  • Revenue Growth
  • CHSCN N/A
  • HUMAW N/A
  • 52 Week Low
  • CHSCN N/A
  • HUMAW $1.18
  • 52 Week High
  • CHSCN N/A
  • HUMAW $1.34
  • Technical
  • Relative Strength Index (RSI)
  • CHSCN 45.85
  • HUMAW N/A
  • Support Level
  • CHSCN $25.10
  • HUMAW N/A
  • Resistance Level
  • CHSCN $25.46
  • HUMAW N/A
  • Average True Range (ATR)
  • CHSCN 0.19
  • HUMAW 0.00
  • MACD
  • CHSCN -0.04
  • HUMAW 0.00
  • Stochastic Oscillator
  • CHSCN 16.67
  • HUMAW 0.00

About CHSCN CHS Inc Preferred Class B Series 2 Reset Rate

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: